Recombinant human erythropoietin pretreatment attenuates heart ischemia-reperfusion injury in rats by suppressing the systemic inflammatory response.

[1]  K. Tobe,et al.  Inhibitory effect of IL-8 on insulin action in human adipocytes via MAP kinase pathway , 2009, Journal of Inflammation.

[2]  Douglas L. Jones,et al.  Erythropoietin Protects the Heart from Ventricular Arrhythmia during Ischemia and Reperfusion via Neuronal Nitric-Oxide Synthase , 2009, Journal of Pharmacology and Experimental Therapeutics.

[3]  L. Xu,et al.  Ulinastatin suppresses systemic inflammatory response following lung ischemia-reperfusion injury in rats. , 2008, Transplantation proceedings.

[4]  H. Jing,et al.  Brain natriuretic peptide limits myocardial infarct size dependent of nitric oxide synthase in rats. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[5]  M. Duan,et al.  Recombinant human erythropoietin (rhEPO) preconditioning on nuclear factor-kappa B (NF-kB) activation & proinflammatory cytokines induced by myocardial ischaemia-reperfusion. , 2006, The Indian journal of medical research.

[6]  K. Maiese,et al.  New avenues of exploration for erythropoietin. , 2005, JAMA.

[7]  M. Curtis,et al.  Brief, intermediate and prolonged ischemia in the isolated crystalloid perfused rat heart: relationship between susceptibility to arrhythmias and degree of ultrastructural injury. , 1995, Journal of molecular and cellular cardiology.

[8]  M. Curtis,et al.  Quantification of arrhythmias using scoring systems: an examination of seven scores in an in vivo model of regional myocardial ischaemia. , 1988, Cardiovascular research.